A study led by biomedical scientists at the University of California, Riverside School of Medicine shows how a genetic ...

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the ...

New 100-week data from the ongoing Phase I/II study of zigakibart, an investigational anti-APRIL monoclonal antibody, ...

Tests in 1,225 patients with the most deadly form of skin cancer reveal for the first time a genetic trait among most of ...

New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, ...

Tests in 1,225 patients with the most deadly form of skin cancer reveal for the first time a genetic trait among most of ...

US FDA grants orphan drug designation to Sanofi’s rilzabrutinib to treat sickle cell disease: Paris Thursday, June 5, 2025, 11:00 Hrs [IST] The US Food and Drug Administration ( ...

Zenas BioPharma has released its corporate presentation for June 2025, providing an insight into its financial and clinical ...

Sanofi's rilzabrutinib earns its fourth orphan drug status from the FDA, this time targeting sickle cell disease.

Paris: Sanofi has received orphan drug designation from the US Food and Drug Administration (FDA) for rilzabrutinib, a novel, ...

Related Disease - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth understanding of historical and ...